Cognition following chimeric antigen receptor T-cell therapy: A systematic review

DISCUSSION: Results of the studies were heterogenous with studies demonstrating stable, improved, or reduced cognition across differing time points. Overall, cognitive symptoms are common particularly in the acute stage (<2 weeks) post-infusion. Most deficits that arise in the acute stage resolve within one to two weeks, however, there is a subset of patients who continue to experience and self-report persistent deficits in the subacute and chronic stages. Future studies are needed to comprehensively analyse cognition using a combination of self-report and psychometric measures following chimeric antigen receptor T-cell therapy in the acute, subacute, and chronic settings.PMID:37837807 | DOI:10.1016/j.jaut.2023.103126

Source: Journal of Autoimmunity - October 14, 2023 Category: Allergy & Immunology Authors: Christina Kazzi Valeriya Kuznetsova Pakeeran Siriratnam Sarah Griffith Shu Wong Constantine S Tam Rubina Alpitsis Andrew Spencer Terence J O'Brien Charles B Malpas Mastura Monif Source Type: research